These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 27254629)

  • 21. Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy.
    Bakakos A; Rovina N; Bakakos P
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of biologics used in the treatment of asthma.
    Neunie OAM; Rabbani W; Baker D; Chambers ES; Pfeffer PE; Kang AS
    Hum Antibodies; 2024; 32(3):121-128. PubMed ID: 38905039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe asthma: When to resort to biological agents.
    Tenero L; Rossignoli S; Piacentini G
    Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():37-39. PubMed ID: 32017206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal antibodies for severe asthma: Pharmacokinetic profiles.
    Matera MG; Calzetta L; Rogliani P; Cazzola M
    Respir Med; 2019 Jul; 153():3-13. PubMed ID: 31136930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological treatments for severe asthma: A major advance in asthma care.
    Busse WW
    Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologic agents for severe asthma patients: clinical perspectives and implications.
    Caruso M; Morjaria J; Emma R; Amaradio MD; Polosa R
    Intern Emerg Med; 2018 Mar; 13(2):155-176. PubMed ID: 29238905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biologics for oral corticosteroid-dependent asthma.
    Yılmaz İ
    Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
    [No Abstract]   [Full Text] [Related]  

  • 29. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
    Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
    Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
    Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Targets for Biological Therapies of Severe Asthma.
    Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
    Front Immunol; 2020; 11():603312. PubMed ID: 33329598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mepolizumab (Nucala°) in asthma.
    Prescrire Int; 2017 Feb; 26(179):38-39. PubMed ID: 30726627
    [No Abstract]   [Full Text] [Related]  

  • 34. [PERSONALIZED TREATMENT OF ASTHMA: THE ISSUE OF ANTI-INTERLEUKIN-5 ANTIBODIES].
    Louis R; Demarche S; Van Hees T; Schleich F
    Rev Med Liege; 2015; 70(5-6):306-9. PubMed ID: 26285457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reslizumab in the treatment of severe eosinophilic asthma: an update.
    Walsh GM
    Immunotherapy; 2018 Jun; 10(8):695-698. PubMed ID: 29554826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Targeted Therapies for Uncontrolled Asthma.
    Corren J
    J Allergy Clin Immunol Pract; 2019; 7(5):1394-1403. PubMed ID: 31076057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma.
    Walsh GM
    Expert Rev Respir Med; 2018 Nov; 12(11):957-963. PubMed ID: 30193532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies in severe asthma: is it worth it?
    Calzetta L; Matera MG; Rogliani P
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):517-520. PubMed ID: 31104515
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
    Matera MG; Calzetta L; Rinaldi B; Cazzola M
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.